Fig. 1

mRNA levels in various types of tumors and their corresponding normal tissue. The RPKM mRNASeq expression profiles are presented for each TCGA disease chart. The results are, in part, based upon the data generated by the TCGA Research Network: https://www.cancer.gov/tcga. This graphical presentation was obtained using the FireBrowse tool. The results for the following tissues (n = tumor samples; normal samples) are presented: BLCA, bladder urothelial carcinoma (n = 49; 11); BRCA, breast invasive carcinoma (n = 699; 88); COAD, colon adenocarcinoma (n = 10); COADREAD, colorectal adenocarcinoma (n = 75); ESCA, esophageal carcinoma (n = 185; 13); HNSC, head and neck squamous cell carcinoma (n = 236; 27); KIPAN, pan-kidney cohort (KICH+KIRC+KIRP) (n = 446; 68); KIRC, kidney renal clear cell carcinoma (n = 433; 68); KIRP, kidney renal papillary cell carcinoma (n = 13); LAML, acute myeloid leukemia (n = 176); LIHC, liver hepatocellular carcinoma (n = 17; 9); LUAD, lung adenocarcinoma (n = 120; 37); LUSC, lung squamous cell carcinoma (n = 212; 17); OV, ovarian serous cystadenocarcinoma (n = 299); READ, rectum adenocarcinoma (n = 65); STAD, stomach adenocarcinoma (n = 272; 33); STES, stomach and esophageal carcinoma (n = 457; 46); THCA, thyroid carcinoma (n = 3); UCEC, uterine corpus endometrial carcinoma (n = 259; 3). A gray box was drawn to indicate that no normal samples were available for that disease cohort. a mRNASeq profiles obtained for apoA1. b mRNASeq profiles obtained for apoE. RPKM, reads per kilobase million values are indicated